OR WAIT null SECS
March 12, 2024
The European company has seen its business increase by 47% in North America.
March 08, 2024
The facility producer’s new innovation hub will offer manufacturing, life sciences, and infrastructure services.
March 06, 2024
The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.
March 01, 2024
The partnership will allow for both companies to provide end-to-end biopharmaceutical manufacturing solutions.
CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.
February 28, 2024
The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.
February 27, 2024
CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.
February 21, 2024
AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.
GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.
February 15, 2024
The company’s Itasca, Ill., facility will offer chemistry, manufacturing, and controls analytical testing support.